When women read about hormone therapy and blood clots, the discussion is almost always about estrogen as a single thing. It is not. How estrogen enters the body changes what it does on the way in, and that difference is one of the better-established findings in menopause medicine.
The first-pass problem
An estrogen tablet is swallowed, absorbed through the gut, and delivered to the liver before it reaches the rest of the circulation. This is called first-pass hepatic metabolism, and it is not a minor detour. The liver responds to that concentrated arrival by changing its output of several proteins, including clotting factors and sex hormone binding globulin.
Estrogen delivered through the skin — a patch, a gel, a spray — is absorbed into the bloodstream directly. It reaches the liver at the same concentration as everything else in circulation. The first-pass effect does not occur.
That single difference in route is why the two are not interchangeable from a risk standpoint, even at doses that produce comparable blood levels of estradiol.
What the evidence shows
The route difference has been measured directly, and the finding has held across two decades and several large datasets. The ESTHER study reported that oral oestrogen carried an increased risk of venous thromboembolism while transdermal oestrogen did not (Scarabin, Oger and Plu-Bureau, Lancet, 2003). A pooled analysis in the BMJ five years later reached the same conclusion across the studies available at that point (Canonico and colleagues, 2008). And a 2019 analysis of two large UK primary care databases — routine prescribing rather than trial conditions — again found the risk attached to oral preparations and not to transdermal ones (Vinogradova, Coupland and Hippisley-Cox, BMJ, 2019).
The same pattern turns up in outcomes other than clotting. An analysis of 112,240 women on oestrogen-only therapy found that those taking pills had a 14% higher risk of being diagnosed with hypertension than those using patches or creams.
Two things should be said plainly alongside that.
First, baseline risk is not zero for anyone, and it is not the same for everyone. Personal or family history of clotting, certain inherited clotting disorders, obesity, immobility, smoking and recent surgery all shift it. A route of administration does not override an individual risk profile.
Second, most of the evidence here is observational rather than from head-to-head randomized trials designed around this specific endpoint. That is a real limitation, and it is why the transdermal route is best described as the preferred one for women at elevated clotting risk, rather than oral estrogen being called unsafe for everyone.
Why this is not the same as "patches are better than gels"
Patches, gels and sprays are all transdermal. They share the same route and the same avoidance of first-pass metabolism. There is no good evidence that one of them is clinically superior to another for safety or effectiveness.
Where they differ is in practical fit — how often you apply them, whether adhesive irritates your skin, whether transfer to another person is a concern in your household, and how a given schedule fits your life. Those differences are real and worth discussing, but they are a separate conversation from the one on this page. We have written about them separately.
What this means for your options
If you are considering hormone therapy, the route is a decision that should be made deliberately rather than by default. Reasonable questions to bring to any provider:
- What route are you recommending, and why that one for me specifically?
- Do I have any personal or family history that changes the calculation?
- Are there reasons in my case to prefer oral estrogen despite the difference in clotting risk?
- What would make you change the route later?
There are legitimate reasons a clinician may still recommend an oral formulation for a particular patient. The point is that the reason should be stated rather than assumed.
Where this sits in a full work-up
Route of delivery is one decision inside a larger one. Before it comes the question of whether hormone therapy is indicated at all, which depends on symptoms, timing, medical history and what a complete panel actually shows — including thyroid and stress hormones, which produce overlapping symptoms and are frequently the reason a woman feels unwell.
We test those as part of the same work-up rather than as a separate appointment, and we discuss delivery route once we know what we are treating.
Frequently asked questions
Is transdermal estrogen safer than oral estrogen?
For venous thromboembolism specifically, the evidence favors the transdermal route, particularly for women with elevated baseline clotting risk. "Safer" is too broad a word for the whole picture — safety depends on your history, your dose, and what else you are taking.
Does progesterone affect clot risk?
The type of progestogen used alongside estrogen has been examined separately, and formulations differ. This should be discussed with your clinician as part of the same decision.
I have been on oral estrogen for years without a problem. Should I switch?
Not necessarily, and not on your own. Bring it up at your next appointment so the decision is made with your history in front of both of you.
Does the difference apply to vaginal estrogen?
Low-dose vaginal estrogen used for genitourinary symptoms is a different situation with different systemic absorption, and is generally considered separately from systemic therapy.
